The Rising Incidence and Poor Outcomes of Enteropathy-associated T-cell Lymphoma

Isabel A. Hujoel,Margaux L.A. Hujoel

DOI: https://doi.org/10.14309/ajg.0000000000002666

2024-01-20

The American Journal of Gastroenterology

Abstract:Introduction: Enteropathy-associated T-cell Lymphoma (EATL) is associated with celiac disease. With the rising prevalence of celiac disease, we hypothesized that the prevalence of EATL is also increasing. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database, which is a population-based United States (US) cancer surveillance program. We used the ICD-O3 code 9717/3 to identify patients with EATL diagnosed between 2000 and 2020. Incidence rates were calculated using the SEER*Stat software and annual percent change was calculated using the Joinpoint software. Log-rank tests were used to evaluate for significant difference in survival curves between groups. A cox-proportional hazards regression model was used for continuous variables and quantifying association strength of predictors. Results: 463 cases of EATL were identified (273 male, 190 female) with a median age of 65 (range 23-90+). The majority of cases were at an advanced stage at diagnosis and were treated with a combination of surgery and chemotherapy. Median survival time was 6 months. The 2000-2020 age-adjusted incidence rate per 100,000 people was 0.014, and the incidence increased between 2000 and 2020, with an annual percent change of 2.58 (p<0.05). Increased age at diagnosis and lack of treatment had significant impacts on survival while sex, year of diagnosis, race, and time between diagnosis and treatment had no significant impact on survival. Discussion: There was a significant increase in the incidence of EATL in the US between 2000 and 2020. Survival of EATL remains poor and unchanged over the past two decades.

gastroenterology & hepatology